Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
|
|
Viracta Therapeutics, Inc. (VIRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/10/2023 |
SC 13D/A
| Schindel Yair Chaim reports a 19.4% stake in Viracta Therapeutics, Inc. |
| 03/10/2021 |
SC 13D/A
| New Enterprise Associates 12, Limited Partnership has filed a Schedule 13D for Viracta Therapeutics, Inc. |
| 11/07/2017 |
SC 13D/A
| Bay City Capital Fund V, L.P. reports a 5.3% stake in Sunesis Pharmaceuticals, Inc. |
| 07/09/2010 |
SC 13D/A
| Growth Equity Opportunities Fund, LLC reports a 19% stake in Sunesis Pharmaceuticals, Inc. |
| 07/01/2010 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
| 11/09/2009 |
SC 13D/A
| WARBURG PINCUS EQUITY PARTNERS LP reports a 4.8% stake in Sunesis Pharmaceuticals, Inc. |
| 11/06/2009 |
SC 13D/A
| ALTA BIOPHARMA PARTNERS III LP reports a 28.5% stake in Sunesis Pharmaceuticals, Inc. |
| 11/03/2009 |
SC 13D/A
| WARBURG PINCUS EQUITY PARTNERS LP reports a 8.8% stake in Sunesis Pharmaceuticals, Inc. |
| 11/03/2009 |
SC 13D/A
| BAY CITY CAPITAL LLC has filed a Schedule 13D for Sunesis Pharmaceuticals, Inc. |
| 07/21/2009 |
SC 13D/A
| WARBURG PINCUS EQUITY PARTNERS LP reports a 9.9% stake in Sunesis Pharmaceuticals, Inc. |
| 07/14/2009 |
SC 13D/A
| WARBURG PINCUS EQUITY PARTNERS LP reports a 12.2% stake in Sunesis Pharmaceuticals, Inc. |
|
|